Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divalproex Sodium in Children With ASD and Epileptiform EEG
NCT01170325Phase 2Withdrawn
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2010
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Divalproex Sodium with Placebo (2 arms). Primary endpoint: Reduction of epileptiform EEG discharges at 24 weeks. Planned start Jun 2010; status: withdrawn.
02
Drugs
divalproex sodium
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01170325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170325.